Eupraxia Pharmaceuticals (EPRX) AI Stock Analysis

• Market Cap: C$209.15M
• Dividend Yield: N/A
• Average Volume (3M): 50.35K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.81
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: CA
• Employees: 29
• Sector: Healthcare
• Sector Strength: 77
• Industry: Biotechnology
• EPS (TTM): -1.24
• Shares Outstanding: 35,622,555
• 10 Day Avg. Volume: 42,437
• 30 Day Avg. Volume: 50,352
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• Price to Cash Flow (P/CF): -3.50
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: C$17.17
• Price Target Upside: 197.06% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

Eupraxia Pharmaceuticals' stock score reflects its early-stage growth potential, highlighted by initial revenue generation. However, significant challenges remain due to ongoing unprofitability and liquidity issues. Technical indicators are neutral, and valuation metrics emphasize the speculative nature of investing in this biotech company at this stage.

Eupraxia Pharmaceuticals Business Overview & Revenue Model

Company Description

Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to approved drugs. Its product candidates address therapeutic areas with a high unmet medical need and strive to provide improved patient benefit by delivering targeted, long-lasting activity with fewer side effects. Its lead product candidate, EP-104IAR, is in development for the treatment of pain due to osteoarthritis of the knee. In addition, it is developing a pipeline of earlier-stage long-acting formulations.

How the Company Makes Money

Eupraxia Pharmaceuticals generates revenue through the development and licensing of its proprietary drug formulations and technologies. The company primarily focuses on advancing its lead product candidates through clinical trials and regulatory approval processes, with the aim of eventual commercialization. Revenue streams include potential upfront and milestone payments from strategic partnerships and licensing agreements with larger pharmaceutical companies. Additionally, once its products receive market approval, Eupraxia anticipates generating revenue from product sales, royalties, and ongoing licensing fees. The company's financial performance is significantly influenced by the success of its clinical trials, regulatory approvals, and the establishment of partnerships with key players in the pharmaceutical industry.

Eupraxia Pharmaceuticals Financial Statement Overview

Summary

Eupraxia Pharmaceuticals is in a growth phase, with initial revenue generation marking a positive step. However, profitability and liquidity issues, coupled with a historically high debt load, present significant challenges. Continued focus on revenue growth and cost management will be vital for future financial health.

Income Statement

Eupraxia Pharmaceuticals has shown a significant improvement in revenue with a TTM figure of $2.98 million, up from zero in previous years, indicating a positive growth trajectory. However, the company is still operating at a substantial loss, with negative net income, EBIT, and EBITDA margins, reflecting ongoing challenges in achieving profitability.

Balance Sheet

The company's debt-to-equity ratio has improved as stockholders' equity turned positive in the recent TTM period. However, the equity ratio is low, and the high historical liabilities indicate potential risk. The improvement in stockholders' equity and reduction in total liabilities are positive signs, but overall financial stability remains a challenge.

Cash Flow

Negative operating and free cash flows highlight liquidity challenges. However, there is an improvement in free cash flow over time, reducing from previous periods. The company has managed financing activities effectively to support cash flow needs, yet the reliance on external financing poses a risk.

Breakdown
TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
2.98M	0.00	0.00	0.00	0.00	0.00
	Gross Profit
1.38M	-209.91K	-193.27K	-111.53K	-116.81K	-201.94K
	EBIT
-28.20M	-36.90M	-22.63M	-20.87M	-2.25M	-6.15M
	EBITDA
-20.67M	-37.40M	-22.14M	-21.96M	-2.01M	-5.94M
	Net Income Common Stockholders
-24.20M	-37.39M	-23.26M	-22.99M	-4.00M	-7.18M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
1.16M	19.34M	24.74M	29.90M	150.13K	1.16M
	Total Assets
3.29M	26.72M	25.88M	31.22M	1.45M	3.29M
	Total Debt
11.94M	10.45M	10.55M	9.56M	12.77M	11.94M
	Net Debt
10.78M	-11.72M	-14.19M	-11.34M	12.62M	10.78M
	Total Liabilities
21.42M	25.55M	14.51M	11.67M	23.12M	21.42M
	Stockholders Equity
-17.69M	2.22M	12.86M	20.39M	-21.21M	-17.69M
Cash Flow		Free Cash Flow
-18.87M	-28.02M	-19.08M	-15.07M	-403.93K	-5.18M
	Operating Cash Flow
-27.03M	-27.92M	-18.78M	-14.64M	-403.93K	-5.17M
	Investing Cash Flow
-65.79K	-99.03K	8.70M	-14.45M	24.62K	-1.90M
	Financing Cash Flow
14.83M	27.84M	13.52M	49.92M	-626.64K	7.40M

Eupraxia Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 5.78
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:EPRX, the sentiment is Positive. The current price of 5.78 is above the 20-day moving average (MA) of 5.68, above the 50-day MA of 4.94, and above the 200-day MA of 4.11, indicating a neutral trend. The MACD of 0.26 indicates Positive momentum. The RSI at 54.56 is Neutral, neither overbought nor oversold. The STOCH value of 43.52 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:EPRX.

Eupraxia Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	49 Neutral	$6.94B	0.41	-53.49%	2.46%	21.23%	-0.63%
EPRX	40 Underperform	C$209.15M	―		―	―	―

Eupraxia Pharmaceuticals Corporate Events

Eupraxia Pharmaceuticals Unveils Promising Drug Delivery Data

Eupraxia Pharmaceuticals has revealed promising pharmacokinetic data for its DiffuSphere™ technology, which enables targeted drug delivery while minimizing systemic exposure for over six months. This innovative approach shows potential for treating various conditions including eosinophilic esophagitis and knee osteoarthritis. The technology delivers drugs directly to target tissues, enhancing efficacy and safety by maintaining a stable release profile.

Eupraxia Pharmaceuticals Showcases Innovation at ACR 2024

Eupraxia Pharmaceuticals is set to present its promising EP-104IAR study at the prestigious American College of Rheumatology Convergence 2024 Annual Meeting. The company’s innovative drug delivery technology shows potential in improving pain management for osteoarthritis patients, which could attract investor interest in its future developments.

Eupraxia Pharmaceuticals Hosts Webinar on Digestive Disorders

Eupraxia Pharmaceuticals is hosting a webinar on November 15, 2024, focusing on Eosinophilic Esophagitis, a rapidly growing digestive disorder. CEO Dr. James A. Helliwell will lead the discussion, highlighting the company’s innovative drug delivery technology aimed at addressing unmet medical needs.

Eupraxia Pharmaceuticals Reports Promising Trial Results

Eupraxia Pharmaceuticals has announced promising results from their RESOLVE trial for the treatment of eosinophilic esophagitis, with the fifth cohort showing significant improvements in patient outcomes and histology scores. Notably, one patient achieved complete histological remission, and no serious adverse events were reported across all cohorts.

Eupraxia Pharmaceuticals Reports Q3 Progress and Funding

Eupraxia Pharmaceuticals reported advances in its clinical trials and financial results for the third quarter of 2024, including positive data from their RESOLVE and SPRINGBOARD trials. The company also secured C$44.5 million in funding and strengthened its management team, despite a net loss of $6.0 million.